CryositeASX:CTE +8.49%51 FCF Margin % is -29.34% as of Dec. 2025. GuruFocus rates ASX:CTE with a GF Score™ of 51/100 and a GF Value™ of A$0.94 (Modestly Overvalued). Among 204 Medical Diagnostics & Research companies, Cryosite ranks worse than 62.75% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cryosite's Free Cash Flow for the
six
months ended in Dec. 2025 was A$-2.43 Mil. Cryosite's Revenue for the
six
months ended in Dec. 2025 was A$8.27 Mil. Therefore, Cryosite's FCF Margin % for the quarter that ended in Dec. 2025 was -29.34%.
The historical rank and industry rank for Cryosite's FCF Margin % or its related term are showing as below:
ASX:CTE'
s FCF Margin % Range Over the Past 10 Years
Min: -11.33 Med: 6.71 Max: 18.17
Current: -11.33
During the past 13 years, the highest FCF Margin % of Cryosite was 18.17%. The lowest was -11.33%. And the median was 6.71%.
ASX:CTE's FCF Margin % is ranked worse than 62.75% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs ASX:CTE: -11.33
Cryosite FCF Margin % Related Terms
Cryosite FCF Margin % Historical Data
* Premium members only.
The historical data trend for Cryosite's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CTE vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Cryosite's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryosite FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Cryosite's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryosite (ASX:CTE) has a FCF Margin % of -29.34% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cryosite and its competitors. According to the industry distribution chart, Cryosite ranks #128 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 62.7%.
Is Cryosite's FCF Margin % too high?
Cryosite's current FCF Margin % is -29.34%. Based on the distribution chart, Cryosite ranks #128 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Cryosite has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cryosite ranks #128 out of 204 companies for FCF Margin %. This places Cryosite in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cryosite and its competitors. Cryosite's current FCF Margin % is -29.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.94, compared to a current price of A$1.15 — trading 22.3% above its estimated fair value. The current FCF Margin % is -29.34%. Cryosite's overall GF Score™ is 51/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current FCF Margin % is -29.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryosite (ASX:CTE) Overvalued in 2026?
Based on GuruFocus' analysis, Cryosite stock appears to be overvalued.
The current stock price of A$1.15 is trading 22.3% above its estimated GF Value™ of A$0.94.
GuruFocus considers Cryosite to be Modestly Overvalued.
Key valuation signals for ASX:CTE:
FCF Margin %: -29.34%
GF Value™: A$0.94 vs. price of A$1.15 (22.3% above fair value)
No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score
Get the complete analysis for ASX:CTE
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTE has been successfully added to your 
